MACH32 Secures Significant Contract from BARDA
MACH32, a promising medical technology start-up based in Alberta, has achieved a significant milestone by securing an Advanced Research and Development contract from the Biomedical Advanced Research and Development Authority (BARDA). This contract underscores MACH32's commitment to developing crucial interventions for life-threatening bleeding resulting from traumatic injuries.
Innovative Approach to Bleeding Control
The focus of this contract is the development of an intramuscular formulation of Tranexamic Acid (TXA). TXA is a vital drug that effectively prevents blood clots from breaking down, helping to control bleeding in emergency situations. Currently available only as an intravenous medication, TXA poses logistical challenges in emergency and pre-hospital settings. MACH32’s approach aims to provide a user-friendly intramuscular option that can be rapidly administered by first responders.
The Importance of Controlling Bleeding
Uncontrolled bleeding is a leading cause of preventable deaths worldwide, emphasizing the urgent need for effective interventions. By innovating an easier method of TXA delivery, MACH32 aims to improve outcomes for patients suffering from traumatic injuries. With its new formulation, TXA can be administered quickly, potentially saving lives during critical moments.
The Vision for TXA Autoinjectors
Dr. Marc Curial, CEO of MACH32, expressed his long-term vision for making TXA available in an autoinjector format resembling an EpiPen. This vision reflects a commitment to empowering first responders and enhancing trauma care capabilities in emergency situations. The recent contract award from BARDA is a step toward realizing this goal.
Backing and Funding for the Project
The contract, valued at approximately $750,000 USD, is set to be completed over an 18-month timeline. This support highlights the federal commitment to improving medical responses in traumatic situations.
Further Support from BARDA’s RePAIR Program
BARDAs initiatives, particularly the RePAIR program, are instrumental in supporting innovations aimed at enhancing medical responses. The funding from BARDA represents a significant investment in the development of novel medical technologies that aim to reduce mortality rates associated with severe injuries.
About MACH32
MACH32 is dedicated to its mission of saving lives by preventing hemorrhage, leveraging advanced technology to deliver effective solutions in critical situations. By designing the IMSAFE intramuscular autoinjector for TXA, they are actively working to ensure that life-saving treatments become more accessible in pre-hospital care settings. Their vision is clear: to enhance trauma care, ensuring timely and effective interventions that contribute to saving lives.
Frequently Asked Questions
What is the purpose of the contract awarded to MACH32?
The contract aims to support MACH32 in developing an intramuscular formulation of Tranexamic Acid (TXA) for controlling life-threatening bleeding.
Why is there a need for an intramuscular formulation of TXA?
An intramuscular formulation allows for easier and quicker administration in emergency settings, overcoming the challenges associated with IV delivery.
How much is the contract worth?
The contract is valued at approximately $750,000 USD and is expected to be completed within 18 months.
What is MACH32’s long-term vision for TXA delivery?
Dr. Curial envisions making TXA available in a format similar to an EpiPen to enhance accessibility for first responders during emergencies.
How does MACH32 plan to improve trauma care?
By simplifying TXA delivery with their innovative autoinjector, MACH32 aims to increase access and efficiency of trauma care in critical situations.
